Tucaxen 150 (Tucatinib) 150 mg Tablets

Indicated for the treatment of adult patients with:

• 🔹 HER2-positive unresectable or metastatic breast cancer: in combination with trastuzumab and capecitabine.
• 🔹 After prior anti-HER2 therapy: in patients previously treated with one or more HER2-directed regimens.
• 🔹 Brain metastases: may be particularly beneficial in patients with CNS involvement due to demonstrated intracranial activity.

Packaging: 150 mg tablets.

⚠️ ADMINISTRATION PROTOCOL:

• Standard Dose: Usually 300 mg twice daily in combination with other anticancer agents, as prescribed by the treating physician.
• Food Intake: Can be taken with or without food.
• Administration: Swallow the tablets whole; do not chew, crush, or split.
• Schedule: Take approximately every 12 hours at the same times each day.
• Monitoring: Liver function and gastrointestinal toxicity should be monitored during treatment.

• Hypersensitivity to Tucatinib or any component of the product.
• Pregnancy and breastfeeding.
• Severe hepatic impairment.
• Use with caution in patients with severe diarrhea, dehydration, hepatotoxicity, or concomitant use of drugs affecting CYP2C8 and CYP3A.

Common adverse reactions include:

• 📉 Gastrointestinal: Diarrhea, nausea, vomiting, stomatitis, abdominal pain.
• 🩸 Liver: Increased ALT, AST, and bilirubin.
• 💢 General: Fatigue, weakness, decreased appetite.
• 🦶 Skin: Palmar-plantar erythrodysesthesia syndrome (more common with capecitabine), rash.
• ⚠️ Other: Dehydration, increased creatinine, anemia.